Showing 5691-5700 of 7297 results for "".
- UCB: Study Data for Cimzia and Bimekizumab Presented at EADVhttps://practicaldermatology.com/news/ucb-data-for-cimzia-and-at-eadv/2457606/UCB has presented new findings on Cimzia® (certolizumab pegol) and one of its key pipeline molecules, bimekizumab, for the treatment of moderate-to-severe chronic plaque psoriasis (PSO), along with findings from an international survey on physicians’ perceptions about treating women wit
- New Study Examines Safety and Efficacy of Higher Dose Botox Cosmetichttps://practicaldermatology.com/news/new-study-examines-safety-and-efficacy-of-higher-dose-botox-cosmetic/2457609/Allergan plc conducted a clinical trial to evaluate the duration of effect and safety of Botox Cosmetic 40, 60, and 80 unit doses versus Botox Cosmetic 20 unit dose in patients with moderate to severe glabellar lines. The primary efficacy endpoint was met and was statistically significant f
- Business News: Candela Acquires Ellipsehttps://practicaldermatology.com/news/business-news-candela-acquires-ellipse/2457616/Candela Corporation has acquired Ellipse, a Danish medical device company that manufactures and markets Intense Pulsed Light (IPL) and laser-based platforms for a wide variety of medical and aesthetic skin treatments. Financial terms of the agreement were not disclosed. “The
- Canfield Scientific Acquires Leading German Dermoscopy Company VISIOMED AGhttps://practicaldermatology.com/news/canfield-scientific-acquires-leading-german-dermoscopy-company-visiomed-ag/2457621/Canfield Scientific has acquired German company VISIOMED AG, which designs and manufactures dermoscopy systems. The resulting business has decades of experience in aesthetic documentation, 3D imaging, clinical photography, and reflected light microscopy leading to more choices and services for cu
- JW Pharmaceutical Signs Global Out-licensing Agreement for Atopic Dermatitis Drug Candidate with LEO Pharmahttps://practicaldermatology.com/news/jw-pharmaceutical-signs-global-out-licensing-agreement-for-atopic-dermatitis-drug-candidate-with-leo-pharma/2457626/JW Pharmaceutical and LEO Pharma A/S have signed a global licensing agreement for JWP’s novel atopic dermatitis drug candidate, JW1601, under which, LEO Pharma will gain the exclusive rights to develop and commercialize JW1601 globally excluding Korea where JWP will maintain its exclusivity
- AbbVie to Present New Data at 27th EADV Congresshttps://practicaldermatology.com/news/abbvie-to-present-new-data-at-27th-eadv-congress/2457625/AbbVie will present new data across investigational medicines and Humira® (adalimumab) at the 27th European Academy of Dermatology and Venereology (EADV) Congress, September 12-1
- Demand for Vegan Cosmetics Expected to Soarhttps://practicaldermatology.com/news/demand-for-vegan-cosmetics-to-soar-bi-2025/2457631/The global vegan cosmetics market size is projected to reach $20.8 billion by 2025, progressing at a Compound Annual Growth Rate (CAGR) of 6.3 percent during the forecast period. Spiraling demand for vegan cosmetics among millennials is one of the primary growth stimulants of the market,
- Wake Forest Researchers: #2 in Probiotic Advancementhttps://practicaldermatology.com/news/wake-forest-researchers-2-in-probiotic-advancements/2457638/Scientists at Wake Forest School of Medicine say they have developed a probiotic “cocktail” derived from gut bacteria strains found in infant feces that may help increase the body’s ability to produce short-chain fatty acids (SCFAs). “Short-chain fa
- FDA Adds Four Tropical Diseases to Priority Review Voucher Programhttps://practicaldermatology.com/news/fda-adds-four-tropical-diseases-to-priority-review-voucher-program/2457639/The FDA announced the addition of Lassa fever, chikungunya virus disease, rabies and cryptococcal meningitis to the list of tropical diseases.
- Report: Psoriasis in America in 2018https://practicaldermatology.com/news/report-psoriasis-in-america-in-2018/2457640/Recently released psoriasis survey results reveal that only 10 percent of patients feel their condition is under control with their current treatment plans; meanwhile, their symptoms—and the mental emotional effects of those symptoms—are overwhelming. The survey, "